USP and Public Policy
Left
Refine Your Search
Significant global health gains have been made in the last few decades, in part thanks to increased access to prevention, therapeutics, and services provided by government donors and global financing…
Learn More
Harnessing information to inform effective action to reduce vulnerabilities and prevent or mitigate disruptions in the global supply of quality medicines.
Learn More
Promoting geographic diversification of the manufacturing base for U.S. drug products can help reduce supply chain vulnerabilities. Published December 2023.
Learn More
The U.S. Pharmacopeia (USP) recognizes that global coordination, harmonization, and convergence efforts among governments and other stakeholders can facilitate and streamline responses and solutions…
Learn More
USP Comment Letter to Senators Sanders and Cassidy and Representatives McMorris-Rodgers and Pallone ( ranking members of the Senate HELP Committee and House Energy and Commerce Committee) regarding…
Learn More
Identifying and addressing vulnerabilities in the upstream pharmaceutical supply chain are essential to mitigating and preventing drug shortages and to ensuring patients have access to the critical…
Learn More
USP Global Public Policy Position: Fostering the Use of Novel Excipients in Drug Products; Published 2024.
Learn More
USP Comments to Congressional Request for Information (RFI) regarding policy solutions to secure and enhance domestic medical supply chains. Submitted on October 4, 2024.
Learn More
USP Comment Letter: Submitted to Office of the United States Trade Representative on Comments on Promoting Supply Chain Resilience (USTR-20240002) (2024)
Learn More